Pharmaceutical News

RSS

Kowa announces data of LIVALO vs. Crestor on pharmacodynamics of warfarin

Kowa Pharmaceuticals America, Inc. today announced data assessing the effect of LIVALO (pitavastatin) compared with Crestor (rosuvastatin) on steady-state pharmacodynamics (PD) of warfarin by measuring international normalized ratio (INR) in healthy adult subjects.

14 Feb 2012

Abbott's Tacrolimus assay provides consistent medication monitoring for organ transplant patients

A new study published in the journal Clinical Chemistry reported Abbott's ARCHITECT Tacrolimus assay provides accurate and consistent medication monitoring for patients taking tacrolimus, an immunosuppressive medication, after receiving solid organ transplantation.

14 Feb 2012

Stress protein effectively activates replication of HBV in liver cells

People who have received a donor organ need lifelong immunosuppressant drugs to keep their immune system from attacking the foreign tissue. However, with a suppressed immune system, many infectious agents turn into a threat. Infections such as with human cytomegalovirus and a certain type of human polyomavirus frequently cause complications in transplant recipients.

14 Feb 2012

Karo Bio decides to discontinue development program for eprotirome

Karo Bio AB (publ) has decided to discontinue the development program for eprotirome after an animal study has demonstrated unwanted effects following long-term exposure. The planned spin-off of the preclinical part of operations will not proceed.

14 Feb 2012

Supply of childhood leukemia drug nearly exhausted

A medicine to treat children's leukemia is in such short supply that hospitals may run out within weeks; meanwhile, families of people with Alzheimer's disease are clamoring to use a skin-cancer drug after a promising study in mice.

14 Feb 2012

FDA requests a budget of $4.5 billion to protect and promote public health

The U.S. Food and Drug Administration is requesting a budget of $4.5 billion to protect and promote the public health as part of the President's fiscal year (FY) 2013 budget – a 17 percent increase over the FDA enacted budget for FY 2012.

14 Feb 2012

FDA accepts Gilead's Truvada sNDA and grants Priority Review

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.

14 Feb 2012

Norwegian government introduces legal limits for 20 illegal drugs and medicines

Legal limits for twenty illegal drugs and medicines with an abuse potential have been introduced by the Norwegian government. Norway is the first country to define both impairment-based legislative limits and limits for graded sanctions for drugs other than alcohol. The Norwegian Institute of Public Health participated to provide the scientific basis for the new limits.

14 Feb 2012

Compound makes imipenem 16 times more effective against antibiotic-resistant K. pneumoniae

North Carolina State University chemists have created a compound that makes existing antibiotics 16 times more effective against recently discovered antibiotic-resistant "superbugs."

14 Feb 2012

Scientists test new 'therapeutic vaccine' against HIV on volunteers

Scientists from the Antwerp Institute of Tropical Medicine, Antwerp University Hospital and Antwerp University have tested a new 'therapeutic vaccine' against HIV on volunteers. The participants were so to say vaccinated with their own cells.

13 Feb 2012

Help combat antibiotic resistance with better patient communication

The latest NPS News highlights the vital role that prescribers play in limiting the spread of antibiotic resistance, and reviews the latest evidence about antibiotic resistance in the individual.

13 Feb 2012

Tenofovir associated with significant risk of kidney damage and chronic kidney disease

Tenofovir, one of the most effective and commonly prescribed antiretroviral medications for HIV/AIDS, is associated with a significant risk of kidney damage and chronic kidney disease that increases over time, according to a study of more than 10,000 patients led by researchers at the San Francisco VA Medical Center and the University of California, San Francisco (UCSF).

13 Feb 2012

Merck's ZIOPTAN for reducing elevated IOP receives FDA approval

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has approved ZIOPTANTM (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution.

13 Feb 2012

Ocean Nutrition Canada purchases Alicorp fish oil refining plant

Ocean Nutrition Canada (ONC) the world's largest Omega-3 ingredient supplier, today announced its acquisition of a fish oil refining plant in Piura, Peru. With the purchase of the plant, ONC will now offer its customers a completely integrated supply chain, from primary processing through to finished ingredient.

13 Feb 2012

Athletes with lumbar disc herniations may benefit from epidural steroid injections

The use of epidural steroid injections may be a more efficient treatment option for lumbar disc herniations, according to research presented today at the American Orthopaedic Society for Sports Medicine's Specialty Day in San Francisco.

13 Feb 2012

OncoSec to commence OMS ElectroImmunotherapy Phase II trial in MCC

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.

13 Feb 2012

Censorship of public health websites by Russian drug agency an 'assault' on HIV prevention

"Amidst pro-democracy protests, the Russian authorities have taken what is an ongoing assault on HIV prevention to the next level by moving to silence public health advocates whose only infraction has been to spread lifesaving information online and to criticize the government for its own failures," Eka Iakobishvili, a human rights analyst at Harm Reduction International, and Claudia Stoicescu, an analyst on Harm Reduction International's public health research team, write in this Huffington Post opinion piece.

13 Feb 2012